Eli Lilly Expands Irish Manufacturing with Additional $1B Investment

Investment Amount:
Eli Lilly is investing an additional $1 billion in its Limerick, Ireland manufacturing site, bringing the total investment to $2 billion.

Expansion Purpose:
The expansion aims to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer’s disease.

Advanced Technologies:
The site will utilize advanced technologies such as machine learning, AI, and automated robotics and systems to enable right-first-time execution.

Job Creation:
The expansion will create an additional 150 jobs for highly skilled workers, including engineers, scientists, quality assurance professionals, and operations personnel, totaling 450 employees at the facility.

Production Timeline:
Production of biologic active ingredients for Lilly medicines is expected to start in 2026.

Sustainability:
The Limerick site is designed to operate with 35% lower energy intensity, use 40% less water, and generate 15% less waste than traditional biopharmaceutical manufacturing processes.

Additional Investment:
The company also unveiled a new $800M facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly’s latest diabetes and obesity treatments.